Company intelligence / Profile preview
Yuhan
Seoul, Seoul, South Koreayuhan.co.kr ↗
- Ownership
- Public · 000100
- Employees
- ~2000
- Development stage
- Other
01
Overview
Yuhan is a leading South Korean pharmaceutical company with over two dozen innovative drug candidates in its pipeline. It has achieved commercial success with products like Leclaza for non-small cell lung cancer, which is approved as both second-line and first-line therapy in Korea. The company anticipates global approvals for key assets soon, especially through partnerships such as with Johnson & Johnson. Its R&D focus includes oncology, metabolism/fibrosis, immunology, and anti-inflammation.
- Therapeutic areas
- Infectious DiseasesEndocrinologyOncologyImmunologyCardiovascular
- Modalities
- Small moleculeBiologicFusion proteinProbiotics
- Industry
- Biotech
02
Drug pipeline
69 assets68 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $4B
- Total revenue
- $1.6B
- Enterprise value
- $4B
Beyond the preview
Go deeper on Yuhan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yuhan.